SEC Ruling Could Allow Greater Transparency On Drug Pricing
This article was originally published in The Pink Sheet Daily
Gilead and Vertex appealed shareholder requests to disclose the processes behind pricing decisions for Sovaldi, Harvoni and Kalydeco, but SEC rules it does not constitute micromanagement of the companies.
You may also be interested in...
In the first half of 2013, two drugs for serious, ultra-rare diseases will have launched in the U.S. priced at $250,000 annually. One is encountering minimal resistance among payers; the other is expected to face a hard road. Plus a look at Celgene/Forma, Bayer/Conceptus, Soligenix/Intrexon; Regeneron/Sanofi and more.
“This type of activity always emerges during a crisis where people will take advantage of others’ desperation and fear,” says acting Commissioner Janet Woodcock in FDLI conference keynote. Regulated industries’ data are needed to continue responding to COVID-19 and prepare for “what comes next.”
Coronavirus Notebook: Heterologous Vaccine Study Shows Positive Results, UK Offers Earlier Second Dose To Vulnerable People
The European Medicines Agency has extended the time that Comirnaty can spend in a fridge after defrosting and could this week issue advice to member states on sotrovimab for use in COVID-19 patients. Norway’s BerGenBio has published top-line data from a Phase II trial of of bemcentinib, and IcanoMAB has outlined the potential of its anti-IL-1R7 antibody.